Periostin predicts all-cause mortality in male but not female end-stage renal disease patients on hemodialysis
Cardiorenal Medicine · 2024
DOI: 10.1159/000539765 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cardiorenal Medicine, 2024. Verfasst von Xitong Li und 10 weiteren Autor:innen. Beteiligte Einrichtung: Fifth Department of Medicine (Nephrology/Endocrinology/Rheumatology/Pneumology), University Medical Centre Mannheim, University of Heidelberg, Mannhe…. Hauptthemen laut MEDLINE: Renal Dialysis, Cell Adhesion Molecules, Kidney Failure, Chronic. Die Arbeit wurde bisher 1-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
Periostin is a matricellular protein. Elevated serum concentrations of periostin have been reported in patients with various cardiovascular diseases, including heart failure. Patients with end-stage renal disease have a substantially increased risk for cardiovascular diseases. However, there is a lack of clinical studies to clarify the prognostic significance of systemic periostin on all-cause mortality in patients with end-stage renal disease on hemodialysis.
Methods
313 stable end-stage renal disease patients were recruited and followed for five years concerning all-cause mortality. At baseline, we collected blood samples and clinical data. Serum periostin concentrations were measured using a certified ELISA.
Results
The optimal cut-off value for serum periostin regarding all-cause mortality, calculated through ROC analysis, was 777.5 pmol/l. Kaplan-Meier survival analysis using this cut-off value demonstrated that higher periostin concentrations are linked to higher all-cause mortality (log-rank test: P = 0.002). Subgroup analysis revealed that serum periostin concentrations only affected all-cause mortality in male but not in female patients (P = 0.002 in male patients and P = 0.474 in female patients). Multivariate Cox regression analyses, adjusted for confounding factors, likewise showed that elevated serum periostin concentrations were positively associated with all-cause mortality in male (P = 0.028) but not in female patients on hemodialysis (P = 0.313).
Conclusion
Baseline serum periostin is an independent risk factor for all-cause mortality in male patients with chronic renal disease on hemodialysis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Fifth Department of Medicine (Nephrology/Endocrinology/Rheumatology/Pneumology), University Medical Centre Mannheim, University of Heidelberg, Mannheim, Germany, lixitong0729@gmail.com.
- Department of Medicine, Charité - Universitätsmedizin Berlin, Berlin, Germany, lixitong0729@gmail.com.
- Fifth Department of Medicine (Nephrology/Endocrinology/Rheumatology/Pneumology), University Medical Centre Mannheim, University of Heidelberg, Mannheim, Germany.
- Department of Medicine, Charité - Universitätsmedizin Berlin, Berlin, Germany.
- Second Medical Faculty, Charles University of Prague, Prague, Czechia.
- HMU - Health and Medical University, Potsdam, Germany.
Zitieren
APA
Li, X., Liu, Y., Hocher, J. G., Chu, C., Reichetzeder, C., Kalk, P., Szakallova, A., Chen, X., Krämer, B. K., Tepel, M., & Hocher, B. (2024). Periostin predicts all-cause mortality in male but not female end-stage renal disease patients on hemodialysis. Cardiorenal Medicine. https://doi.org/10.1159/000539765
Vancouver
Li X, Liu Y, Hocher JG, Chu C, Reichetzeder C, Kalk P, et al. Periostin predicts all-cause mortality in male but not female end-stage renal disease patients on hemodialysis. Cardiorenal Medicine. 2024. doi:10.1159/000539765
BibTeX
@article{Li2024,
author = {Li, Xitong and Liu, Yvonne and Hocher, Johann-Georg and Chu, Chang and Reichetzeder, Christoph and Kalk, Philipp and Szakallova, Angelika and Chen, Xin and Krämer, Bernhard K and Tepel, Martin and Hocher, Berthold},
title = {Periostin predicts all-cause mortality in male but not female end-stage renal disease patients on hemodialysis},
journal = {Cardiorenal Medicine},
year = {2024},
doi = {10.1159/000539765}
}
EUVIMED